Literature DB >> 17635750

Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease.

Patricia R Wahl1, Michel Le Hir, Alexander Vogetseder, Alexandre Arcaro, Astrid Starke, Ying Waeckerle-Men, Andreas L Serra, Rudolf P Wuthrich.   

Abstract

AIM: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by an imbalance between tubular epithelial cell proliferation and apoptosis. We have previously shown that the mammalian target of rapamycin (mTOR) signalling pathway is aberrantly activated in the cystic kidneys of Han:SPRD rats with ADPKD. Because the Akt kinase is an upstream regulator of mTOR, we hypothesized that the activity of Akt could be enhanced in the kidneys of Han:SPRD rats.
METHODS: Reverse transcription-polymerase chain reaction, western blot, enzyme-linked immunosorbent assay and immunohistochemistry were used to analyse Akt expression in rat polycystic kidneys.
RESULTS: Wild-type (+/+) and heterozygous (Cy/+) Han:SPRD rats showed constitutive expression of Akt-1, -2 and -3 mRNA by reverse transcription-polymerase chain reaction analysis with no significant difference between Cy/+ and +/+ kidneys. Western blotting and enzyme-linked immunosorbent assay showed a significant increase in phosphorylated Akt in Cy/+ compared with +/+ kidneys. The pattern of immunoreactivity for phosphorylated Akt in kidney sections was the same in +/+ and in Cy/+ rats, with very low levels in interphase cells, but extremely bright signals in mitotic cells, beginning with the onset of the prophase. The in vivo incorporation of bromo-deoxyuridine revealed approximately a ninefold higher rate of proliferation in Cy/+ cyst epithelia compared with normal tubule epithelia in +/+ rats, while the expression of the cell cycle marker Ki67 revealed approximately a sixfold higher rate of proliferation. In summary, enhanced phosphorylation of Akt can be demonstrated in Cy/+ kidneys which correlates with a markedly elevated proliferation rate of epithelial cells in cysts. Mitotic but not resting cells display strong phosphorylation of Akt.
CONCLUSION: Because Akt is a proximal target of mTOR, its inhibition with specific antagonists could be useful to prevent or halt cystogenesis in ADPKD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635750     DOI: 10.1111/j.1440-1797.2007.00811.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  14 in total

1.  2-Hydroxyestradiol slows progression of experimental polycystic kidney disease.

Authors:  Sharon Anderson; Terry T Oyama; Jessie N Lindsley; William E Schutzer; Douglas R Beard; Vincent H Gattone; Radko Komers
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

Review 2.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 3.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

4.  Constitutive activation of the mTOR signaling pathway within the normal glomerulus.

Authors:  Gearoid M McMahon; Dipak Datta; Sarah Bruneau; Martin Kann; Myda Khalid; Jacqueline Ho; Tatsuichiro Seto; Jordan A Kreidberg; Isaac E Stillman; David M Briscoe
Journal:  Biochem Biophys Res Commun       Date:  2012-07-22       Impact factor: 3.575

5.  Integrin-Linked Kinase Signaling Promotes Cyst Growth and Fibrosis in Polycystic Kidney Disease.

Authors:  Archana Raman; Gail A Reif; Yuqiao Dai; Aditi Khanna; Xiaogang Li; Lindsay Astleford; Stephen C Parnell; James P Calvet; Darren P Wallace
Journal:  J Am Soc Nephrol       Date:  2017-05-18       Impact factor: 10.121

6.  Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models.

Authors:  Thomas A Natoli; Laurie A Smith; Kelly A Rogers; Bing Wang; Svetlana Komarnitsky; Yeva Budman; Alexei Belenky; Nikolay O Bukanov; William R Dackowski; Hervé Husson; Ryan J Russo; James A Shayman; Steven R Ledbetter; John P Leonard; Oxana Ibraghimov-Beskrovnaya
Journal:  Nat Med       Date:  2010-06-20       Impact factor: 53.440

Review 7.  Cyclic AMP-mediated cyst expansion.

Authors:  Darren P Wallace
Journal:  Biochim Biophys Acta       Date:  2010-11-28

8.  PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.

Authors:  Daisuke Yoshihara; Hiroki Kurahashi; Miwa Morita; Masanori Kugita; Yoshiyuki Hiki; Harold M Aukema; Tamio Yamaguchi; James P Calvet; Darren P Wallace; Shizuko Nagao
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-08

Review 9.  Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.

Authors:  Vicente E Torres; Alessandra Boletta; Arlene Chapman; Vincent Gattone; York Pei; Qi Qian; Darren P Wallace; Thomas Weimbs; Rudolf P Wüthrich
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

10.  Evidence that TMEM67 causes polycystic kidney disease through activation of JNK/ERK-dependent pathways.

Authors:  E Du; Hong Li; Shunying Jin; Xuemei Hu; Mengsheng Qiu; Ruifa Han
Journal:  Cell Biol Int       Date:  2013-04-16       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.